Nanjing Pharmaceutical Co (SHSE:600713) FFO


SHSE:600713 Nanjing Pharmaceutical Co Ltd SHSE:600713
61 GF Score
Price ¥5.17
GF Value ¥4.50
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nanjing Pharmaceutical Co FFO?

FFO (Funds from operations) only applies to REITs.

SHSE:600713
61GF Score
Nanjing Pharmaceutical Co Ltd SHSE:600713
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nanjing Pharmaceutical Co (SHSE:600713) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.17 is trading 14.9% above its estimated GF Value™ of ¥4.50. GuruFocus considers Nanjing Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600713:

  • FFO:
  • GF Value™: ¥4.50 vs. price of ¥5.17 (14.9% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanjing Pharmaceutical Co Business Description

Address No. 55, Andemen Street, Building 2, Yuhuatai District, Jiangsu Province, Nanjing, CHN, 210002
Nanjing Pharmaceutical Co Ltd is engaged in the pharmaceutical service business.
61GF Score

Get the complete analysis for SHSE:600713

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.17
Price
¥4.50
GF Value